Highlights on medical treatment of uterine fibroids
S Angioni, MN D'Alterio… - Current Pharmaceutical …, 2021 - ingentaconnect.com
Uterine fibroids (leiomyomas or myomas) are the most frequent benign tumors in women.
Heavy menstrual bleeding with resultant anemia, dysmenorrhea, chronic pelvic pain …
Heavy menstrual bleeding with resultant anemia, dysmenorrhea, chronic pelvic pain …
Sex steroid receptors in polycystic ovary syndrome and endometriosis: insights from laboratory studies to clinical trials
Polycystic ovary syndrome (PCOS) and endometriosis are reproductive disorders that may
cause infertility. The pathology of both diseases has been suggested to be associated with …
cause infertility. The pathology of both diseases has been suggested to be associated with …
90 YEARS OF PROGESTERONE: Selective progesterone receptor modulators in gynaecological therapies
HOD Critchley, RR Chodankar - Journal of molecular …, 2020 - jme.bioscientifica.com
Abnormal uterine bleeding (AUB) is a chronic, debilitating and common condition affecting
one in four women of reproductive age. Current treatments (conservative, medical and …
one in four women of reproductive age. Current treatments (conservative, medical and …
Effect of the novel selective progesterone receptor modulator vilaprisan on ovarian activity in healthy women
B Schütt, MH Schultze‐Mosgau… - The Journal of …, 2018 - Wiley Online Library
This randomized, double‐blind, parallel‐group study in healthy young women investigated
the effect of treatment with vilaprisan (0.5, 1, 2, or 4 mg/day for 12 weeks) on ovarian function …
the effect of treatment with vilaprisan (0.5, 1, 2, or 4 mg/day for 12 weeks) on ovarian function …
CYP3A4‐mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1‐mediated effects on bilirubin glucuronidation in humans
N Chattopadhyay, T Kanacher… - British Journal of …, 2018 - Wiley Online Library
Aims The primary aim of the present study was to quantify the effects of rifampicin, a strong
cytochrome P450 (CYP) 3A4 inducer, on the pharmacokinetics of the new selective …
cytochrome P450 (CYP) 3A4 inducer, on the pharmacokinetics of the new selective …
Characterization of the pharmacokinetics of vilaprisan: bioavailability, excretion, biotransformation, and drug–drug interaction potential
MH Schultze-Mosgau, J Höchel, O Prien… - Clinical …, 2018 - Springer
Background and objectives In-vitro data suggest that clearance of vilaprisan is mediated by
cytochrome P450 3A4 (oxidation) and aldoketoreductases (reduction). To fully understand …
cytochrome P450 3A4 (oxidation) and aldoketoreductases (reduction). To fully understand …
Potential synergism between ulipristal acetate and vitamin D3 in uterine fibroid pharmacotherapy–2 case studies
M Ciebiera, B Męczekalski, K Łukaszuk… - Gynecological …, 2019 - Taylor & Francis
This is a preliminary report of the first cases of successful simultaneous use of ulipristal
acetate (UPA) and vitamin D3 in uterine fibroid (UF) oral treatment in humans. We present …
acetate (UPA) and vitamin D3 in uterine fibroid (UF) oral treatment in humans. We present …
The latest advances in the pharmacological management of endometriosis
G Hartner, H Husslein, L Kuessel… - Expert Opinion on …, 2023 - Taylor & Francis
Introduction Endometriosis is a benign disease, characterized by a wide range of symptoms
and different degrees of severity, which is why therapy should be individually adapted to the …
and different degrees of severity, which is why therapy should be individually adapted to the …
Vilaprisan for treating uterine fibroids
GB Melis, M Neri, B Piras, AM Paoletti… - Expert opinion on …, 2018 - Taylor & Francis
Introduction: The medical strategy to antagonize myoma size and related-symptoms is to
reduce estrogen and progesterone activity on myomas. This can be obtained with the GnRH …
reduce estrogen and progesterone activity on myomas. This can be obtained with the GnRH …
[HTML][HTML] Variation of outcome reporting in studies of interventions for heavy menstrual bleeding: a systematic review
NAM Cooper, R Papadantonaki, S Yorke… - Facts, Views & Vision …, 2022 - ncbi.nlm.nih.gov
Background Heavy menstrual bleeding (HMB) detrimentally effects women. It is important to
be able to compare treatments and synthesise data to understand which interventions are …
be able to compare treatments and synthesise data to understand which interventions are …